Results 41 to 50 of about 1,768,893 (247)

Live Attenuated Cold-Adapted Influenza Vaccines [PDF]

Cold Spring Harbor Perspectives in Medicine, 2020
Live attenuated, cold-adapted influenza vaccines exhibit several desirable characteristics, including the induction of systemic, mucosal, and cell-mediated immunity resulting in breadth of protection, ease of administration, and yield. Seasonal live attenuated influenza vaccines (LAIVs) were developed in the United States and Russia and have been used ...
openaire   +2 more sources

Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant

Journal of Virology
Vaccination against seasonal influenza is considered an effective means of reducing morbidity and mortality. Live-attenuated vaccines offer more protection against influenza than inactivated vaccines as they efficiently induce cellular immunity and ...
Tadasuke Naito, Hiroshi Ushirogawa, Miyuki Kunishio, Haruka Yano, Susumu Saito, Taisei Higeuchi, Kazuki Fujita, Mineki Saito   +7 more
doaj   +1 more source

Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines

mBio, 2019
Nonstructural protein 1 (NS1) of influenza virus is a key virulence element with multifunctional roles in virus replication and a potent antagonist of host immune response.
Pui Wang, Min Zheng, Siu-Ying Lau, Pin Chen, Bobo Wing-Yee Mok, Siwen Liu, Honglian Liu, Xiaofeng Huang, Conor J. Cremin, Wenjun Song, Yixin Chen, Yik-Chun Wong, Haode Huang, Kelvin Kai-Wong To, Zhiwei Chen, Ningshao Xia, Kwok-Yung Yuen, Honglin Chen   +17 more
doaj   +1 more source

Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity [PDF]

, 2020
The efficacy of the intranasally (i.n.) delivered live attenuated influenza vaccine (LAIV) is variable and, in some seasons, suboptimal. In this study, we report that LAIV exhibits cross-protective efficacy in mice, potentially associated with cellular ...
Furuya, Y., Pardo, J., Yoichi Furuya, Danushka K Wijesundara, Williams, C.M., Clare M Williams, Roy, S., Julian Pardo, Wijesundara, D.K., Sreeja Roy   +9 more
core   +1 more source

Attenuation of the influenza virus by microRNA response element in vivo and protective efficacy against 2009 pandemic H1N1 virus in mice

International Journal of Infectious Diseases, 2015
Background: The 2009 influenza pandemics underscored the need for effective vaccines to block the spread of influenza virus infection. Most live attenuated vaccines utilize cold-adapted, temperature-sensitive virus.
Chunlai Feng, Mingming Tan, Wenkui Sun, Yi Shi, Zheng Xing   +4 more
doaj   +1 more source

Influenza Virus Carrying a Codon-Reprogrammed Neuraminidase Gene as a Strategy for Live Attenuated Vaccine

Vaccines, 2023
Live attenuated influenza vaccines offer broader and longer-lasting protection in comparison to inactivated influenza vaccines. The neuraminidase (NA) surface glycoprotein of influenza A virus is essential for the release and spread of progeny viral ...
Ji Dong, Zhenyuan Dong, Pei Feng, Yu Gao, Jiashun Li, Yang Wang, Lujie Han, Zhixia Li, Qian Wang, Xuefeng Niu, Chufang Li, Weiqi Pan, Ling Chen   +12 more
doaj   +1 more source

Codon pair bias and viral vaccine design [PDF]

, 2015
The authors acknowledge the long term support of the Wellcome Trust and the Biotechnology and Biological Sciences Research Council.Live attenuated vaccines (LAVs) have prevented morbidity and mortality against a number of important viral diseases (such ...
Tulloch, Fiona Ashley, Ryan, Martin Denis, Pathania, Uday Singh, Luke, Garry Alec   +3 more
core   +1 more source

Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species [PDF]

, 2011
Highly pathogenic avian influenza A viruses (HPAIV) of the H5N1 subtype occasionally transmit from birds to humans and can cause severe systemic infections in both hosts.
García-Sastre, Adolfo, García-Sastre, A., Rong Hai, Hale Benjamin G., Pena, Lindomar, Hai, Rong, John Steel, Manicassamy Balaji, Daniel R. Pérez, Pérez Daniel R., Manicassamy, Balaji, Pena, L., Benjamin G. Hale, Sutton, T., Zsuzsanna T Varga, Troy Sutton, Sutton Troy, Varga Zsuzsanna T., Hale, B.G., Varga, Zsuzsanna T, Pena Lindomar, Zsuzsanna T. Varga, Hale, Benjamin G, Balaji Manicassamy, Adolfo García-Sastre, Schmolke, M., Hai Rong, Hai, R., Daniel R Pérez, Pérez, D.R., Sutton, Troy, Steel, John, Pérez, Daniel R, Steel, J., Steel John, García-Sastre Adolfo, Manicassamy, B., Mirco Schmolke, Lindomar Pena, Benjamin G Hale, Schmolke, Mirco, Varga, Z.T., Schmolke Mirco   +42 more
core   +2 more sources

Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada’s experience with the live-attenuated influenza vaccine

, 2021
Over the last several years, the recommended use of the live-attenuated influenza vaccine (LAIV) for children has evolved in the United States (US) in response to evidence of a potential decrease in LAIV effectiveness based on post-market monitoring ...
Kelsey Young, Matthew Tunis, Linlu Zhao, Althea House, Rob Stirling   +4 more
core   +1 more source

Targeted Degradation of Picornaviral 3C Protease via PROTACs Confers High Barrier to Viral Resistance and Broad‐Spectrum Antiviral Activity

Advanced Science, EarlyView.
This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng, Junyu Chen, Yingyue Pang, Yuanyuan Zhang, Siqian Chen, Guoliang You, Xiaoman Tian, Zhongxin Xu, Jing Wang, Luqing Shang   +9 more
wiley   +1 more source